Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. GRDN
GRDN logo

GRDN Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
36.690
Open
35.820
VWAP
35.91
Vol
287.06K
Mkt Cap
2.26B
Low
35.390
Amount
10.31M
EV/EBITDA(TTM)
22.23
Total Shares
63.32M
EV
2.23B
EV/OCF(TTM)
25.14
P/S(TTM)
1.59
Guardian Pharmacy Services, Inc. is a pharmacy services company. The Company provides a range of technology-enabled services designed to help residents of long-term care facilities (LTCFs) adhere to drug regimen. It offers compliance packaging service for repackaging and dispensing prescription and non-prescription pharmaceuticals in accordance with physician orders and delivers the medications to LTCFs for administration to individual residents. It organizes each resident’s medications into individual unit dose or multi-unit dose packaging in accordance with specific drug distribution rounds that occur at LTCFs at specific times throughout the day. Its pharmacy workflow software helps to manage and track drug dispensing via a structured and scalable workflow process, including the use of barcode technology. It offers Guardian Compass, which includes dashboards created to help local pharmacies plan, track and optimize business operations.
Show More

Events Timeline

(ET)
2026-05-06
17:00:00
Q1 Revenue of $336.6M Exceeds Consensus
select
2026-05-06
17:00:00
Guardian Pharmacy Affirms FY26 Revenue View of $1.40B-$1.42B
select
2026-05-06
16:50:00
Guardian Pharmacy Files Automatic Class A Common Stock Offering
select
2026-03-19 (ET)
2026-03-19
07:40:00
Share Offering Size Increased to 6M Shares
select
2026-03-19
07:40:00
Share Offering Size Increased to 6.0M Shares
select
2026-03-19
06:20:00
Guardian Pharmacy Prices 6M Share Public Offering at $31 Each
select

News

seekingalpha
9.5
05-07seekingalpha
Guardian Pharmacy Q1 Earnings Beat Expectations
  • Strong Earnings Performance: Guardian Pharmacy Services reported a Q1 non-GAAP EPS of $0.29, beating expectations by $0.05, which reflects the company's robust profitability and boosts investor confidence.
  • Significant Revenue Growth: The company achieved Q1 revenue of $336.6 million, exceeding forecasts by $6.71 million, indicating its competitive strength and sustained customer demand, further solidifying its market position.
  • Net Income and Adjusted EBITDA: Q1 net income stood at $13.5 million with adjusted EBITDA at $29.8 million, demonstrating positive progress in cost control and operational efficiency, which supports sustainable growth moving forward.
  • Optimistic Outlook: The company raised its annual adjusted EBITDA forecast midpoint to $125 million from $122 million while maintaining its revenue outlook midpoint at $1.41 billion, reflecting management's confidence in future performance and recognition of market potential.
seekingalpha
9.5
05-07seekingalpha
Guardian Pharmacy Services Reports Q1 2026 Earnings Amid IRA Challenges
  • Revenue Growth: Guardian Pharmacy Services reported Q1 2026 revenue of $336.6 million, reflecting a 2% year-over-year increase despite a significant 60% decline in pricing for branded drugs under the IRA framework, demonstrating resilience in challenging conditions.
  • Adjusted EBITDA Guidance Increase: Management raised full-year adjusted EBITDA guidance to $123 million to $127 million, incorporating a $3 million benefit recognized in Q1, indicating strong profitability amid new policy challenges.
  • Increase in Resident and Script Volumes: The company reported a 10% year-over-year increase in total residents to approximately 207,000 and a similar 10% rise in script volumes, highlighting robust market demand and effective expansion of its customer base.
  • Capital Markets Activity: The company executed an offering of 6.9 million Class A shares priced at $31 each during the quarter, although it currently has no plans to utilize the newly filed shelf registration, reflecting a cautious approach to capital management.
CNBC
6.0
04-27CNBC
Major Wall Street Rating Updates on Monday
  • Cohu Rating Reiteration: Jefferies reiterates its Buy rating on Cohu with a price target of $55, viewing the company as an emerging enabler of higher-complexity semiconductor testing, which could enhance its market position significantly.
  • Rollins Upgrade: Rothschild & Co Redburn upgrades Rollins from Neutral to Buy, raising the price target from $51.90 to $66, indicating a 16% upside, as they see the current share price as an attractive entry point for investors.
  • Nutrien Upgrade: Barclays upgrades Nutrien from Equal Weight to Overweight, increasing the price target from $80 to $85, anticipating continued strength in the nitrogen segment due to the Iran conflict, which positions the company favorably in the market.
  • Galaxy Digital Initiation: Chardan initiates coverage of Galaxy Digital with a Buy rating, highlighting its attractive position in the digital asset ecosystem and potential for integration with traditional financial markets, which could drive future growth.
Newsfilter
1.0
04-23Newsfilter
Guardian Pharmacy Services to Attend 2026 Healthcare Conference
  • Conference Participation: Guardian Pharmacy Services will attend the Bank of America 2026 Healthcare Conference in Las Vegas on May 13, 2026, where CEO Fred Burke will participate in a fireside chat at 9:20 a.m. PDT, showcasing the company's leadership in long-term care pharmacy services.
  • Investor Engagement: The event will feature a live audio webcast accessible through Guardian Pharmacy Services' website, allowing investors, analysts, media, and the public to engage, thereby enhancing transparency and interaction with stakeholders.
  • Business Model: Guardian partners with long-term care facilities to deliver medications and technology-enabled services aimed at improving medication adherence, which helps reduce care costs and enhance clinical outcomes, highlighting its competitive edge in the industry.
  • Network Expansion: As of December 31, 2025, Guardian operates 61 pharmacies, with 54 being full-service, serving nearly 205,000 residents, demonstrating its ongoing growth and influence in the long-term care market.
Newsfilter
9.5
04-14Newsfilter
Guardian Pharmacy Services to Release Q1 2026 Financial Results
  • Earnings Release Announcement: Guardian Pharmacy Services has announced that it will release its Q1 2026 financial results after market close on May 6, 2026, with management hosting a conference call at 4:30 p.m. Eastern Time, reflecting the company's commitment to transparency and investor communication.
  • Conference Call Details: The conference call will be available via audio webcast, with investors able to participate through a designated link or by dialing a dedicated number for U.S. and Canadian participants, while international participants can access the call through provided international numbers, ensuring broad investor engagement and information dissemination.
  • Company Overview: Guardian Pharmacy Services is one of the nation's leading long-term care pharmacy service providers, dedicated to partnering with long-term care facilities to deliver medications and technology-enabled services aimed at reducing care costs and improving clinical outcomes, highlighting its significant position in the industry.
  • Network Expansion: As of December 31, 2025, Guardian operates 61 pharmacies, 54 of which are full-service, serving approximately 205,000 residents, indicating the company's ongoing growth in the long-term care market and its commitment to customer service.
NASDAQ.COM
8.5
04-09NASDAQ.COM
Biotech Stocks Reach New 52-Week Highs
  • Relay Therapeutics Progress: Relay Therapeutics' drug candidate Zovegalisib showed promising results in clinical trials, with a 7.64% stock price increase to $14.64 on Wednesday, indicating the company's potential in treating HR+/HER2- breast cancer, with initial data expected in the first half of 2026.
  • MapLight Therapeutics High: MapLight Therapeutics' stock reached $25.79 during trading yesterday, up from its IPO price of $17.00, reflecting market optimism for its drug ML-007C-MA targeting schizophrenia and Alzheimer's disease, with trial results anticipated in Q3 2026.
  • Oruka Therapeutics Development: Oruka Therapeutics' ORKA-001 and ORKA-002 are in clinical trials for psoriasis, with the stock hitting $64.61, showcasing market confidence in its drugs, and significant data expected in Q2 2026.
  • Spyre Therapeutics Clinical Trials: Spyre Therapeutics' stock reached $54.33 yesterday, reflecting market interest in its investigational therapies, particularly the SKYLINE trial for active ulcerative colitis, with preliminary data expected in Q3 2026.
Wall Street analysts forecast GRDN stock price to rise
2 Analyst Rating
Wall Street analysts forecast GRDN stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
34.00
Averages
34.50
High
35.00
Current: 0.000
sliders
Low
34.00
Averages
34.50
High
35.00
Oppenheimer
Outperform
maintain
$38 -> $43
AI Analysis
2026-05-07
New
Reason
Oppenheimer
Price Target
$38 -> $43
AI Analysis
2026-05-07
New
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Guardian Pharmacy to $43 from $38 and keeps an Outperform rating on the shares following the company's earnings report. Overall, the results reflect Guardian's effort to offset the IRA impact, which will allow investors to return their focus to the strong underlying growth tailwinds, the firm says.
BofA
Allen Lutz
initiated
$42
2026-04-27
Reason
BofA
Allen Lutz
Price Target
$42
2026-04-27
initiated
Reason
BofA analyst Allen Lutz initiated coverage of Guardian Pharmacy with a Buy rating and $42 price target. The firm sees "a long path of elevated growth" given Guardian's strong track record, industry changes that are putting pressure on smaller peers and Guardian's "best in class" purchasing and reimbursement model, the analyst tells investors.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for GRDN
Unlock Now

Valuation Metrics

The current forward P/E ratio for Guardian Pharmacy Services Inc (GRDN.N) is 29.33, compared to its 5-year average forward P/E of 25.31. For a more detailed relative valuation and DCF analysis to assess Guardian Pharmacy Services Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
25.31
Current PE
29.33
Overvalued PE
28.34
Undervalued PE
22.28

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
15.85
Current EV/EBITDA
19.18
Overvalued EV/EBITDA
18.03
Undervalued EV/EBITDA
13.67

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.16
Current PS
1.50
Overvalued PS
1.35
Undervalued PS
0.96

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

best 3 stocks for swing trading today
Intellectia · 83 candidates
Price: $5.00 - $150.00Price Change Pct: $3.00 - $15.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
WLK logo
WLK
Westlake Corp
14.49B
PAM logo
PAM
Pampa Energia SA
4.56B
SLVM logo
SLVM
Sylvamo Corp
1.59B
LOVE logo
LOVE
Lovesac Co
197.77M
HPK logo
HPK
Highpeak Energy Inc
897.14M
EAF logo
EAF
GrafTech International Ltd
161.89M
THERE IS A DAY TRADING SIGNAL
Intellectia · 21 candidates
Rsi Category: moderate, overboughtPrice Change Pct: $3.00 - $15.00Relative Vol: >= 2Support Resistance Relationship: PriceBreakResistanceThree Min Rate Of Change: >= 0.5%
Ticker
Name
Market Cap$
top bottom
TAOP logo
TAOP
Taoping Inc
11.92M
NAMI logo
NAMI
Jinxin Technology Holding Co
42.62M
OVID logo
OVID
Ovid Therapeutics Inc
303.31M
INTJ logo
INTJ
Intelligent Group Ltd
10.84M
LSH logo
LSH
Lakeside Holdings Ltd
29.99M
CV logo
CV
CapsoVision Inc
289.49M

Whales Holding GRDN

A
Aristotle Capital Boston, LLC
Holding
GRDN
+2.63%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Guardian Pharmacy Services Inc (GRDN) stock price today?

The current price of GRDN is 35.65 USD — it has decreased -1.22

What is Guardian Pharmacy Services Inc (GRDN)'s business?

Guardian Pharmacy Services, Inc. is a pharmacy services company. The Company provides a range of technology-enabled services designed to help residents of long-term care facilities (LTCFs) adhere to drug regimen. It offers compliance packaging service for repackaging and dispensing prescription and non-prescription pharmaceuticals in accordance with physician orders and delivers the medications to LTCFs for administration to individual residents. It organizes each resident’s medications into individual unit dose or multi-unit dose packaging in accordance with specific drug distribution rounds that occur at LTCFs at specific times throughout the day. Its pharmacy workflow software helps to manage and track drug dispensing via a structured and scalable workflow process, including the use of barcode technology. It offers Guardian Compass, which includes dashboards created to help local pharmacies plan, track and optimize business operations.

What is the price predicton of GRDN Stock?

Wall Street analysts forecast GRDN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRDN is34.50 USD with a low forecast of 34.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Guardian Pharmacy Services Inc (GRDN)'s revenue for the last quarter?

Guardian Pharmacy Services Inc revenue for the last quarter amounts to 336.60M USD, increased 2.21

What is Guardian Pharmacy Services Inc (GRDN)'s earnings per share (EPS) for the last quarter?

Guardian Pharmacy Services Inc. EPS for the last quarter amounts to 0.21 USD, increased 40.00

How many employees does Guardian Pharmacy Services Inc (GRDN). have?

Guardian Pharmacy Services Inc (GRDN) has 3600 emplpoyees as of May 12 2026.

What is Guardian Pharmacy Services Inc (GRDN) market cap?

Today GRDN has the market capitalization of 2.26B USD.